<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134758</url>
  </required_header>
  <id_info>
    <org_study_id>P030419</org_study_id>
    <secondary_id>AOM 03041</secondary_id>
    <nct_id>NCT00134758</nct_id>
  </id_info>
  <brief_title>Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients</brief_title>
  <official_title>Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axcan Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant transformation of adenomas of the duodenum is now the leading cause of death in
      familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy.
      Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity
      of duodenal adenomas and prevent such transformation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a randomized double blinded study to evaluate the efficiency of UDCA in the
      treatment of duodenal adenomas. One hundred patients are planned to be included. Fifty will
      receive UDCA and fifty a placebo. Three duodenoscopies are planned: one before inclusion, one
      at the end of the first year of follow-up and one after two years of follow-up at the end of
      the protocol. These duodenoscopies are associated to endoscopies of the ileal reservoir
      performed at the time of restorative proctocolectomy and are recorded numerically. Severity
      of the duodenal adenomas are evaluated according to the SPIGELMAN score. Patients are seen
      every 6 months. Before each endoscopy, blood samples are collected for biliary acid profile
      analysis. Moreover, during endoscopies, duodenal fluid and ileal fluid are collected for
      biliary acid profile analysis, also.

      At the end of the follow-up of the last patients included (nov 2008), biliary acid profile
      analysis will be performed and statistical analysis of the results will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPIGELMAN severity score of duodenal lesion after 2 years of follow-up</measure>
    <time_frame>Baseline, 1 and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular proliferation (Ki 67 and PCNA)</measure>
    <time_frame>At the baseline, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary acid profile</measure>
    <time_frame>At the baseline, 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to the treatment</measure>
    <time_frame>Every 6 months during 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Adenomatous Polyposis Coli, Familial</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodeoxycholic acid during 2 years :
between 40 and 50 kg : 500 mg/day
between 51 and 75 kg : 750 mg/day
between 76 and 100 kg : 1000 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid</intervention_name>
    <description>During 2 years :
between 40 and 50 kg : 500 mg/day
between 51 and 75 kg : 750 mg/day
between 76 and 100 kg : 1000 mg/day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Delursan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During 2 years :
between 40 and 50 kg : 2 tabs/day
between 51 and 75 kg : 3 tabs/day
between 76 and 100 kg : 4 tabs/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 18 and 65 years of age

          -  Weight less than or equal to 100 kg

          -  Restorative proctocolectomy

          -  Activated protein C (APC) mutation identified or more than 100 polyps on the colectomy
             specimen

          -  SPIGELMAN score of duodenal adenoma greater than or equal to 1

          -  Efficient contraceptive treatment for pre-menopausal women

          -  Cooperative patient

          -  Signed consent

          -  Social security insurance

        Exclusion Criteria:

          -  SPIGELMAN score of duodenal adenoma equal to 4 with severe dysplasia

          -  Hepatic disease

          -  Intermesenteric desmoid tumour

          -  Any severe disease

          -  Daily use during the last 3 months of:

               -  aspirin;

               -  non-steroid anti-inflammatory drugs;

               -  tamoxifen;

               -  cholestyramine.

          -  Pregnancy

          -  Breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yann RA Parc, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Digestive Surgery, Saint-Antoine Hospital, Hospital of Paris (AP/HP), Pierre et Marie Curie University, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet. 1989 Sep 30;2(8666):783-5.</citation>
    <PMID>2571019</PMID>
  </reference>
  <reference>
    <citation>Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993 Dec;80(12):1618-9.</citation>
    <PMID>8298943</PMID>
  </reference>
  <reference>
    <citation>Järvinen HJ, Nyberg M, Peltokallio P. Biliary involvement in familial adenomatosis coli. Dis Colon Rectum. 1983 Aug;26(8):525-8.</citation>
    <PMID>6872780</PMID>
  </reference>
  <reference>
    <citation>Spigelman AD, Owen RW, Hill MJ, Phillips RK. Biliary bile acid profiles in familial adenomatous polyposis. Br J Surg. 1991 Mar;78(3):321-5.</citation>
    <PMID>1850640</PMID>
  </reference>
  <reference>
    <citation>Mower HF, Ray RM, Shoff R, Stemmermann GN, Nomura A, Glober GA, Kamiyama S, Shimada A, Yamakawa H. Fecal bile acids in two Japanese populations with different colon cancer risks. Cancer Res. 1979 Feb;39(2 Pt 1):328-31.</citation>
    <PMID>761204</PMID>
  </reference>
  <reference>
    <citation>Hill MJ, Drasar BS, Williams RE, Meade TW, Cox AG, Simpson JE, Morson BC. Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet. 1975 Mar 8;1(7906):535-9.</citation>
    <PMID>47015</PMID>
  </reference>
  <reference>
    <citation>Tanida N, Hikasa Y, Shimoyama T, Setchell KD. Comparison of faecal bile acid profiles between patients with adenomatous polyps of the large bowel and healthy subjects in Japan. Gut. 1984 Aug;25(8):824-32.</citation>
    <PMID>6745720</PMID>
  </reference>
  <reference>
    <citation>van der Werf SD, Nagengast FM, van Berge Henegouwen GP, Huijbregts AW, van Tongeren JH. Colonic absorption of secondary bile-acids in patients with adenomatous polyps and in matched controls. Lancet. 1982 Apr 3;1(8275):759-62.</citation>
    <PMID>6121223</PMID>
  </reference>
  <reference>
    <citation>Wilpart M, Mainguet P, Maskens A, Roberfroid M. Structure-activity relationship amongst biliary acids showing comutagenic activity towards 1,2-dimethylhydrazine. Carcinogenesis. 1983 Oct;4(10):1239-41.</citation>
    <PMID>6616753</PMID>
  </reference>
  <reference>
    <citation>Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994 Oct 1;54(19):5071-4.</citation>
    <PMID>7923119</PMID>
  </reference>
  <reference>
    <citation>Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE, Poupon R. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology. 2003 Jul;38(1):203-9.</citation>
    <PMID>12830003</PMID>
  </reference>
  <reference>
    <citation>Parc Y, Piquard A, Dozois RR, Parc R, Tiret E. Long-term outcome of familial adenomatous polyposis patients after restorative coloproctectomy. Ann Surg. 2004 Mar;239(3):378-82.</citation>
    <PMID>15075655</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <last_update_submitted>July 28, 2009</last_update_submitted>
  <last_update_submitted_qc>July 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christophe Aucan</name_title>
    <organization>Department of clinical research and development</organization>
  </responsible_party>
  <keyword>Treatment of adenomas of the duodenum in FAP patients.</keyword>
  <keyword>Adenoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

